Literature DB >> 19372063

Implementation of European standards of care for cystic fibrosis--control and treatment of infection.

J S Elborn1, M Hodson, C Bertram.   

Abstract

BACKGROUND: Several guidelines on infection control and treatment of infection exist for cystic fibrosis (CF) caregivers, although the extent of implementation is variable.
METHODS: Adherence to European Consensus Guidelines for CF was studied by sending surveys to named healthcare professionals in 487 European CF centres/units. Qualitative data analysis was performed.
RESULTS: A total of 177/547 (32%) surveys were returned. Infection control policies were implemented by most (77%) respondents. Separation of patients with Burkholderia cepacia was more common in adults (95%) than children (9%), and was implemented by 53% of respondents for Pseudomonas aeruginosa. Nebulised colistin plus oral ciprofloxacin was the most common (43%) therapy for P. aeruginosa infection. First infections of P. aeruginosa were usually treated with inhaled tobramycin; 41% of repondents did not intervene until lung function deteriorated. Most exacerbations were treated for less than the recommended period.
CONCLUSIONS: European Consensus Guidelines are widely adhered to. Areas for improvement include: initiating therapy for exacerbations early, separating infected patients and optimising duration of antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372063     DOI: 10.1016/j.jcf.2009.03.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  11 in total

1.  Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo.

Authors:  Gilles Brackman; Paul Cos; Louis Maes; Hans J Nelis; Tom Coenye
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 2.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

3.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients.

Authors:  Andreas Hector; Matthias Kappler; Matthias Griese
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

5.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

6.  Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates.

Authors:  Elodie Olivares; Stéphanie Badel-Berchoux; Christian Provot; Benoît Jaulhac; Gilles Prévost; Thierry Bernardi; François Jehl
Journal:  Front Microbiol       Date:  2017-07-11       Impact factor: 5.640

7.  Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.

Authors:  Zhe Hui Hoo; Frank Peter Edenborough; Rachael Curley; Laura Prtak; Jane Dewar; Mark Ivan Allenby; Julia Anne Nightingale; Martin James Wildman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-06       Impact factor: 3.267

8.  Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers.

Authors:  Suzanne Crowley; Mathias Geldermann Holgersen; Kim Gjerum Nielsen
Journal:  Chron Respir Dis       Date:  2018-07-18       Impact factor: 2.444

9.  In vitro polymyxin activity against clinical multidrug-resistant fungi.

Authors:  Hanane Yousfi; Stéphane Ranque; Jean-Marc Rolain; Fadi Bittar
Journal:  Antimicrob Resist Infect Control       Date:  2019-04-24       Impact factor: 4.887

10.  Improving access to healthcare for paediatric sickle cell disease patients: a qualitative study on healthcare professionals' views.

Authors:  Maite E Houwing; Marit Buddenbaum; Thijs C J Verheul; Anne P J de Pagter; Jacobus N J Philipsen; Jan A Hazelzet; Marjon H Cnossen
Journal:  BMC Health Serv Res       Date:  2021-03-12       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.